

(51) International Patent Classification:
A61K 39/00 (2006.01)(21) International Application Number:
PCT/US2021/019889(22) International Filing Date:
26 February 2021 (26.02.2021)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
62/982,665 27 February 2020 (27.02.2020) US(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichstrasse 35,
4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **BROGDON, Jennifer** [US/US];
Novartis Institutes for Biomedical Research, Inc., 250
Massachusetts Avenue, Cambridge, MA 02139 (US). **DRA-
NOFF, Glenn** [US/US]; 250 Massachusetts Avenue, Cam-
bridge, MA 02139 (US). **GREENE, Michael R.** [US/US];
250 Massachusetts Avenue, Cambridge, MA 02139 (US).
HACK, Anniesha [US/US]; One Health Plaza, East
Hanover, NJ 07936 (US). **KODRASI, Olja** [US/US]; 220
Gardiner Road, Quincy, MA 02169 (US). **PRATICO, Eliz-
abeth Dorothy** [US/US]; 80 Piers Park Lane, Apt 3221,
East Boston, MA 02128 (US). **PRICE, Andrew** [US/US];250 Massachusetts Avenue, Cambridge, MA 02139 (US).
STEIN, Andrew Marc [US/US]; 250 Massachusetts Av-
enue, Cambridge, MA 02139 (US). **RAYO, Amy** [US/US];
250 Massachusetts Avenue, Cambridge, MA 02139 (US).
YANG, Jennifer [US/US]; 250 Massachusetts Avenue,
Cambridge, MA 02139 (US). **GRANDA, Brian Walter**
[US/US]; Novartis Institutes for Biomedical Research, Inc.,
250 Massachusetts Avenue, Cambridge, MA 02139 (US).(72) Inventors: **BONDANZA, Attilio**; Postfach, 4002 Basel
(CH). **ENGELS, Boris**; 250 Massachusetts Avenue, Cam-
bridge, Massachusetts 02139 (US). **LIM, Hyungwook**; 250
Massachusetts Avenue, Cambridge, Massachusetts 02139
(US). **SOHONI, Akash**; 250 Massachusetts Avenue, Cam-
bridge, MA 02139 (US). **TREANOR, Louise**; 250 Massa-
chusetts Avenue, Cambridge, MA 02139 (US). **ZHU, Xu**;
250 Massachusetts Avenue, Cambridge, MA 02139 (US).
GUIMARAES, Carla; Novartis Institutes for Biomedical
Research, Inc., 250 Massachusetts Avenue, Cambridge, MA
02139 (US). **JAYASHANKAR, Shyamali**; 250 Massachu-
setts Avenue, Cambridge, MA 02139 (US). **KOSHY, San-
deep Tharian**; Novartis Institutes for Biomedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, MA 02139
(US). **CEBE, Regis**; Postfach, 4002 Basel (CH).(74) Agent: **KOYMAN, Hannah R.** et al.; Lando & Anastasi,
LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(54) Title: METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS

2+2:



"Knob-into-Hole" (KiH):





FIG. 50A

(57) Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*